8-K: BioCryst Announces Strong 2024 Results and Positive Outlook for 2025

BioCryst reports a 34% year-over-year increase in ORLADEYO net revenue for 2024 and anticipates approaching quarterly profitability in the second half of 2025.

Summary

• BioCryst Pharmaceuticals announced preliminary, unaudited results for 2024, highlighting a significant increase in ORLADEYO net revenue.
• Full year 2024 ORLADEYO net revenue reached $437 million, a 34% increase compared to the previous year.
• Total revenue for 2024 was $450 million, representing a 36% year-over-year growth.
• The company expects 2025 ORLADEYO net revenue to be between $515 million and $535 million.
• Total revenue for 2025, including RAPIVAB, is projected to be between $540 million and $560 million.
• BioCryst anticipates full year 2025 operating expenses to be between $485 million and $495 million, including $60 million in stock-based compensation.
• The company expects to approach quarterly earnings per share (EPS) profitability and positive cash flow in the second half of 2025.
• BioCryst also plans to submit a new drug application for ORLADEYO granules in children under 12 in 2025.
• The company is advancing clinical programs for Netherton syndrome (BCX17725) and diabetic macular edema (avoralstat) in 2025.

Sentiment

Score: 8

Explanation: The document conveys a very positive outlook with strong revenue growth, a clear path to profitability, and expansion into new markets. The risks are acknowledged but do not overshadow the positive momentum.

Positives

• ORLADEYO revenue growth accelerated in 2024, with a 34% annual increase compared to 30% in 2023.
• Over 1,200 U.S. physicians have prescribed ORLADEYO, and thousands of patients have benefited in over 30 countries.
• The company achieved operating profit in 2024 (excluding stock-based compensation).
• BioCryst expects a 20% annual revenue CAGR over the next three years.
• The company expects to be profitable on an EPS basis, with positive cash flow, for full year 2026.

Negatives

• The company's operating expenses are expected to be between $485 million and $495 million in 2025.
• Stock-based compensation is estimated to be $60 million in 2025, which is a significant expense.

Risks

• Actual revenue results for 2024 may differ from the preliminary, unaudited results due to the completion of closing, review, and audit procedures.
• The company's ability to successfully implement and maintain its commercialization plans for ORLADEYO is subject to risk.
• The success of the company's pipeline development plans is not guaranteed.
• Partnerships with third parties may not meet the company's expectations.
• Government actions, including pricing decisions, may not be favorable.
• The commercial viability of ORLADEYO is subject to market acceptance and demand.
• Clinical trials may take longer than expected and may not have positive results.
• The company may not be able to enroll the required number of subjects in planned clinical trials.
• Regulatory agencies may require additional studies or impose restrictions on products and product candidates.
• The company's ability to manage growth and compete effectively is subject to risk.
• The timing for achieving and sustainability of profitability and positive cash flow may not meet management's expectations.
• Actual financial results may not be consistent with expectations.

Future Outlook

BioCryst anticipates continued revenue growth, with a 20% annual CAGR over the next three years, and expects to approach quarterly EPS profitability and positive cash flow in the second half of 2025, with full year profitability in 2026.

Management Comments

• Jon Stonehouse, president and chief executive officer, stated that 2024 was a year of outstanding execution and that the company is moving significantly closer to peak sales of $1 billion for ORLADEYO.
• Charlie Gayer, chief commercial officer, noted that oral, preventative therapy with ORLADEYO is the new benchmark for HAE and that they are excited to bring this option to children under age 12.

Industry Context

The announcement highlights BioCryst's strong position in the hereditary angioedema (HAE) market with ORLADEYO, a once-daily oral treatment, and its expansion into new therapeutic areas. This is in line with the industry trend of developing convenient oral therapies for chronic conditions.

Comparison to Industry Standards

• BioCryst's 34% year-over-year growth in ORLADEYO revenue is strong compared to other pharmaceutical companies in the rare disease space, which often see growth rates in the 10-25% range for established products.
• Companies like Takeda (with TAKHZYRO) and CSL Behring (with HAEGARDA) are key competitors in the HAE market, and BioCryst's growth suggests it is gaining market share.
• The company's focus on oral therapies aligns with a broader industry trend towards patient-friendly administration routes, which is a competitive advantage.
• The planned expansion of ORLADEYO to children under 12 is a significant move, as it addresses an unmet need in the HAE market and could further increase market share.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and path to profitability.
• Employees may be motivated by the company's positive performance and future prospects.
• Patients will benefit from the expansion of ORLADEYO to children and the development of new therapies.
• Suppliers and creditors may view the company as a stable and reliable partner.

Next Steps

• BioCryst will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
• The company plans to submit a new drug application for ORLADEYO granules in children under 12 in 2025.
• Clinical programs for BCX17725 and avoralstat will advance into patient studies in 2025.

Key Dates

Keywords

ORLADEYO, berotralstat, revenue, profitability, HAE, biotechnology, clinical trials, pharmaceuticals, operating expenses, EPS, cash flow